Experimental drugs and drug combinations in pancreatic cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Kroep, J R ^a   Pinedo, H M ^a   Van Groeningen, C J ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil; Chemotherapy; Gemcitabine; Pancreatic carcinoma

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DNA; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MARIMASTAT; PEMETREXED; RALTITREXED; THYMIDYLATE SYNTHASE; TOPOTECAN; UFT;

ANALGESIA; BODY WEIGHT; CONFERENCE PAPER; DNA SYNTHESIS; DRUG BLOOD LEVEL; HUMAN; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0032807118     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S234     Document Type: Conference Paper

References (63)

1. Ahlgren JD: Chemotherapy for pancreatic carcinoma. Cancer 1996; 78:653-63
2. Schilsky RL: Biochemical and clinical pharmacology of 5-fluorouracil. Oncology 1998; 12, Suppl 7: 13-18.
3. Peters GJ, Ackland SP: New antimetabolites in preclinical and clinical development. Exp Opin Invest Drugs 1996; 5: 637-79.
4. Peters GJ, Jansen G: Resistance to antimetabolites, in Schilsky RL, Milano GA, Ratain MJ (eds): In Principles of Antineoplastic Drug Development and Pharmacology. Marcel Rekker Inc., New York 1996: 543-585.
5. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: the role of dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1463-70.
6. DeCaprio JA, Mayer RJ, Gonin R, et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991; 9: 2128-33.
7. Crown J, Casper ES, Botet J et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic carcinoma. J Clin Oncol 1991; 9: 1682-6.
8. Pazdur R, Ajani JJ, Abbruzese JL, et al. Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992; 70: 2073-6.
9. Scheithauer W, Pfeffel F, Kornek G, et al. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2 interferon in advanced adenocarcinoma of the pancreas. Cancer 1992; 70: 1864-6.
10. Rosvold E, Schilder R, Walczak J, et al. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chem & Pharm 1992; 29:305-8.
11. Twelves C, Budman DR, Creaven PJ, et al. Pharmacokinetics and pharmacodynamics of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 1996; 15: 476 (abstr 1509).
12. Findlay M, Van Cutsem E, Kocha W, et al. A randomized phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 227 (abstr 798).
13. Diasio RB: The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 1998; 12, Suppl 7: 23-27.
14. Baker SD, Khor SP, Adjei AA, et al. Pharmacokinetics, bioavailability, and safety study of fluorouracil in patients treated with GW776, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996; 14: 3085-96.
15. Schilsky RL, Hohneker J, Ratain M, et al: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998;16:1450-7.
16. Peters GJ, van der Wilt CL, van Groeningen CJ, et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994; 12: 2035-42.
17. Pazdur R, Meropol NJ, Casper ES, et al. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs 1996; 13: 355-358.
18. Miller KD, Loehrer, Picus J, et al. A phase II trial of multi-targeted antifolate (LY231514) in patients with unresectahle pancreatic cancer. Ann Oncol 1998; 9, Suppl 4: 46 (abstr 220O).
19. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6:102-4.
20. O'Reilly S, Donehower RC, Rowinsky EK, et al. A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anti-Cancer Drugs 1996; 7: 410-14.
21. Scher R, Kosierowski R, Lusch C et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Inv New Drugs 1995; 13: 347-54.
22. Stevenson JP, Scher RM, Kosierowski R, et al. Phase II trial of topotecan as a 31-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998; 34:1358-62.
23. Androulakis N, Kourousis Ch, Dimopoulos AM, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony stimulating factor: A multicenter phase II study. Ann Oncol 1998; 9, Suppl 4: 54 (abstr 255).
24. Whitehead RP, Jacobson J, Brown TD, et al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997; 15: 2414-19.
25. Ruiz van Haperen VWT, Veerman G, Vermorken JB, et al: 2′2′-Difluorodeoxy-cytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 1993; 46: 762-6.
26. Huang P, Chuhh S, Hertel LW, et al: Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
27. Huang P, Plunkett W: A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem 1992; 207:163-7.
28. Tolis C, Peters GJ, Ferreira CG, et al. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer, 1999 (in press).
29. Plunkett W, Huang P, Gandhi V: Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995; 6, Suppl 6: 7-13.
30. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) in patients with advanced pancreatic cancer. Invest New Drugs 1994; 12: 29-34.
31. Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-53.
32. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 2403-13.
33. Oster MW, Gray R, Panasci L, et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986; 57:29-33.
34. Kelsen D, Clifford H, Niedzwiecki D, et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991; 68: 965-9.
35. Aapro MS, Martin C, Hatty S: Gemcitabine - a safety review. Anti-cancer Drugs 1998; 9: 191-201.
36. Van Moorsel CJA, Peters GJ, Pinedo HM: Gemcitabine: future prospects of single agent and combination studies. The Oncologist 1997; 2:127-34.
37. Cascinu S, Silva RR, Barni S et al: Gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a GISCAD phase II study. Proc Am Soc Clin Oncol 1998; 17: 264a (abstr 1013).
38. De Gusmao CBRA, Murad AM, Scalabrini-Neto AO: Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract adenocarcinoma. Proc Am Soc Clin Oncol 1998; 17: 290a (abstr 1116).
39. Borner MM, Maurer CA, Friess H, et al. Gemcitabine and continuous infusion fluorouracil: A phase II study in advanced pancreatic cancer. Ann Oncol 1998: 9, Suppl 4: 51 (abstr 241P).
40. Polyzos A, Tsavaris N, Kosmas C, et al. Gemcitabine plus 5-fluorouracil modulated by leucovorin for advanced pancreatic cancer. Ann Oncol 1998; 9, Suppl 4: 55 (abstr 262).
41. Raderer M, Kornek GV, Valencak J, et al. Phase II trial of gemcitabine, epirubicin, and G-CSF in patients with metastatic pancreatic cancer. Ann Oncol 1998; 9, Suppl 2:169 (abstr 648).
42. Lueck A, Ridwelski K, Lippert H: Phase I study of a treatment of gemcitabine and docetaxel weekly in advanced pancreatic cancer. Ann Oncol 1998; 9, Suppl 4: 52 (abstr 249).
43. Heineman V, Wilke H, Possinger K, et al: Activity and tolerability of gemcitabine plus cisplatin in advanced metastatic pancreatic cancer. Eur J Cancer 1997; 33, Suppl 8: 274 (abstr 1240).
44. Colucci G, Giuliani F, Riccardi F, et al: Gemcitabine alone or with cisplatin in advanced pancreatic cancer: preliminary results of a randomized study of the Southern Italy Oncology Group. Proc Am Soc Clin Oncol 1998; 17: 289a (abstr 1112).
45. Abad A, Arellano A, Brunet J, et al. Gemcitabine plus radiotherapy in stage II-III pancreatic cancer: A phase I trial. Ann Oncol 1998; 9, Suppl 4: 53 (abstr 253).
46. Blackstock Aw, Bernard SA, Richards F, et al. Phase I study of concurrent radiation and twice weekly gemcitabine in advanced/metastatic pancreatic cancer. Proc Am Soc Clin Oncol 1998; 17: 264a (abstr 1015).
47. Hoffman JP, McGinn CJ, Szarka C, et al. A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized, resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1998; 17: 283a (abstr 1090).
48. McGinn CJ, Smith DC, Szarka CE, et al. A phase I study of gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer. Proc Am Soc Clin Oncol 1998; 17:264a (abstr 1014).
49. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1998; 17: 283a (abstr 1091).
50. Bramhall SR: The matrix metalloproteinases and their inhibitors in pancreatic cancer. Intern J Pancreatology 1997; Vol 21: 1-12.
51. Carmichael J, Lederman JA, Woll PJ et al. Phase 1B study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 1998; 17: 232a (abstr 888).
52. Pettit GR, Srirangam JK, Williams MD et al. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anti-Cancer Drug Design 1995; 10: 529-44.
53. Mohammad RM, Dugan MC, Mohamed AN et al. Establishment of a human pancreatic tumor xenograft model - potential application for preclinical evaluation of novel therapeutic agents. Pancreas 1998; 16:19-25.
54. Mohammad RM, Alkatib A, Pettit GR et al. An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice - potential application for preclinical studies. Clin Cancer Res 1998; 4: 887-94.
55. Hall AR, Dix BR, Ocarroll SJ et al. P53-dependent cell death apoptosis is required for a productive adenovirus infection. Nature med. 1998; 4: 1068-72.
56. Dergham ST, Dugan MC, Kucway R, et al. Prevalence and clinical significance of combined K-ras mutation and P53 aberration in pancreatic adenocarcinoma. Int. J Panc. 1997; 21:127-43.
57. Heise C, Sampsonjohannes A, Williams A et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature med. 1997; 3: 639-45.
58. Freytag SO, Rogulski KR, Paielli DL et al. A novel three-prolonged approach to kill cancer cells selectively concomitant viral, double suicide gene, and radiotherapy. Human Gene Ther. 1998; 9:1323-33.
59. Rothmann T, Hengstermann A, Whitaker NJ et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of P53 status in tumor cells. J Virology 1998; 72:9470-8.
60. Mulvihill SJ, Warren RS, Fell S et al. A phase I trial of intratumoral injection with an E1B-attenuated adenovirus, ONYX-015, into unresectable carcinomas of the exocrine pancreas. Proc Am Soc Clin Oncol 1998; 17: 211 (abstr 815).
61. Algren JD: Pancreatic cancer: chemotherapy of advanced disease. In Gastrointestinal Oncology. Philadelphia: JB Lippincott Press. 1992; 227-235.
62. Lutz MP, Koniger M, Adler G et al. Phase II study of weekly high-dose infusional 5-fluorouracil in advanced pancreatic carcinoma. Ann Oncol 1998; 9, Suppl 4: 54 (abstr 257).
63. Wilki N, Schneller J, van Laethem JL et al. Promising early results of oral 5-fluorouracil plus eniluracil (776C85) in patients with advanced adenocarcinoma of the pancreas. Ann Oncol 1998; 9, Suppl 4: 46 (abstr 221O).